
|Videos|November 4, 2021
Controlling ACE and ARB Dosing Can Benefit Treatment of Chronic Kidney Disease
Chi Chu, MD, an assistant professor in the division of nephrology at the University of California San Francisco, discusses how ACE and ARB therapies can be applied to chronic kidney disease, and the benefits of controlling the dosage.
Advertisement
In a Pharmacy Times® interview, Chi Chu, MD, an assistant professor in the division of nephrology at the University of California San Francisco, spoke about his 2021 ASN Kidney Week presentation on the submaximal dose of angiotensin converting enzyme (ACE) inhibitor and angiotensin II receptor blockers (ARB) for individuals with proteinuria.
He discussed how ACE and ARB therapies can be applied to chronic kidney disease, and the benefits of controlling the dosage.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Pharmacists at the Forefront: Initiating, Monitoring, and Identifying Candidates for VMAT2 Therapy
2
Up to 5 Cups of Coffee Daily Safe—and Benficial—for Most Adults
3
Pharmacist Outreach Doubles SGLT2 Inhibitor Uptake in CKD
4
mRNA COVID-19 Booster Outperforms Protein-Based Shot on Antibodies, But Both Cut Infections Over 12 Months
5





































































































